Rodin Therapeutics, Inc.

Proteros Biostructures Gmbh

Adrian Schomburg

Fabian Dey

Martin R Jefson

Russell Thomas

Andreas Schoop

Robert Van Der Burgh

Konstanze Konig Von Paumbshausen

The present invention relates to methods for determining a binding and/or functional interaction of a protein of interest with a nucleosomal substrate wherein at least one of the histone types of the nucleosomal substrate has a homogenous post-translational modification pattern. Further, the invention relates to nucleosomal substrates, wherein at least one of the histone types of the nucleosomal substrate has a homogenous post-translational modification pattern, and to methods for providing such nucleosomal substrates.

Nucleosome substrate assays

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Inhibitors of histone deacetylase

Growing community of inventors

Gräfelfing, Germany

Adrian Schomburg